Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced it has completed dosing in the Company's PHYOX™4 clinical trial, evaluating nedosiran for the treatment of patients with PH3.

Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3

Repare Therapeutics

Should you follow Cathie Wood's latest genomic revolution investments?

2 Biotech Stocks ARK Invest Bought in June

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference.

Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the U.S. FDA's acceptance of the Investigational New Drug (IND) application filed by Lilly for LY3819469.

Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug (IND) Application for LY3819469

Germany-based Boehringer Ingelheim has accepted Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) GalXC RNAi candidate for advancement under the existing agreement between the companies to discover and develop novel therapies for the treatment of chronic liver diseases. Dubbed DCR-LIV2, the compound will be investigated for the treatment of nonalcoholic steatohepatitis (NASH).

Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Boehringer Ingelheim has accepted a GalXC™ RNAi candidate for advancement under the existing agreement between the companies.

Dicerna Announces Boehringer Ingelheim's Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences.

Dicerna to Participate in Upcoming Investor Conferences

Dicerna approached doubling from its 52-week low, then drifted lower recently. Cash was raised recently from a royalty deal; has a runway to 2024. The platform and pipeline remain poised for long-term value.

Dicerna A Buy On Long-Term Potential

Dicerna Pharmaceuticals (DRNA) CEO Doug Fambrough on Q1 2021 Results - Earnings Call Transcript

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -39.29% and -20.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company will release its first quarter 2021 financial results after market close on Thursday, May 6, 2021.

Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021

Royalty Pharma

Royalty Pharma plc (NASDAQ: RPRX) has acquired  Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. The FDA and European Medicines Agency have approved Oxlumo (EMA) for the treatment of primary hyperoxaluria (PH) type 1 and is marketed by Alnylam Pharmaceuticals Inc (NASDAQ: ALNY).

Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront

LEXINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Dicerna today announced that Royalty Pharma has acquired Dicerna's royalty interest in OXLUMO™ (lumasiran) for up to $240 million.

Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) has announced new data from preclinical studies of its GalXC-Plus RNAi technology demonstrating its potential to deliver messenger RNA (mRNA) knockdown against prespecified gene targets across the central nervous system (CNS) and to specific CNS cell types. Data from a preclinical mouse study showed that a single dose of an unconjugated GalXC-Plus molecule produced by the ALDH2 gene resulted in dose-dependent reductions of up to 92% knockdown in target mRNA and lasted through the trial conclusion at 28 days.

Dicerna's RNAi Technology Shows Encouraging Action Against CNS Targets In Animal Studies

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced new data from preclinical studies of its GalXC-Plus RNAi technology within the central nervous system (CNS) at the OPT Congress.

Dicerna's GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will present new nonclinical data discussing the Company's GalXC-Plus™ RNAi technology as part of the OPT Virtual Congress, March 30-31, 2021.

Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will host a webinar on its alcohol use disorder (AUD) candidate, DCR-AUD. The event will take place on March 18, 2021 at 4:30 p.m. ET.

Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today announced that Roche has initiated RG6346 in the Roche sponsored Phase 2 combination trial for the treatment of chronic HBV infection.

Dicerna Announces Roche's Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection

Carnival

Royal Caribbean Cruises

Bank of Montreal

Amicus Therapeutics

Golar LNG

Switch

Truecar Inc

With the trading day more than halfway over, the broad markets pulled back from their impressive start to the week.

Carnival, Royal Caribbean, Switch and More Tuesday Afternoon Analyst Calls

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q4 2020 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update.

Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will release its fourth quarter and full year 2020 financial results after market close on Thursday, Feb. 25, 2021.

Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021

Dicerna has a huge pipeline of both internal and partnered RNAi products, one of which already has positive Phase 3 results. Dicerna has over $600 million in cash with more to come from its lucrative big pharma partnerships.

Dicerna Is A Reasonably Priced Play In The Attractive RNAi Space

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) initiates patient dosing in Phase 1 PHYOX 4 trial evaluating its lead candidate, nedosiran, to treat primary hyperoxaluria, a rare condition characterized by the recurrent kidney and bladder stones. The condition often results in end-stage renal disease.

News for Dicerna Pharmaceuticals Stock (DRNA)